Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Chinese (SSE) Clinical Research and Equipment Industry Analysis

UpdatedJun 12, 2026
DataAggregated Company Financials
Companies27
  • 7D-1.8%
  • 3M-5.2%
  • 1Y15.0%
  • YTDn/a

Over the last 7 days, the Clinical Research and Equipment industry has dropped 1.8%, driven by a pullback from Pharmaron Beijing of 3.0%. Over the past 12 months, the industry was up 15%. Earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the Chinese Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Fri, 12 Jun 2026CN¥523.7bCN¥98.8bCN¥21.9b46.5x24x5.3x
Sun, 10 May 2026CN¥602.8bCN¥98.7bCN¥21.7b57.2x27.7x6.1x
Tue, 07 Apr 2026CN¥585.3bCN¥94.9bCN¥20.7b56.8x28.3x6.2x
Thu, 05 Mar 2026CN¥545.6bCN¥94.5bCN¥18.6b59x29.4x5.8x
Sat, 31 Jan 2026CN¥590.9bCN¥94.3bCN¥18.5b61.8x31.9x6.3x
Mon, 29 Dec 2025CN¥555.5bCN¥94.3bCN¥18.5b61x30x5.9x
Wed, 26 Nov 2025CN¥558.1bCN¥94.3bCN¥18.5b65.7x30.1x5.9x
Fri, 24 Oct 2025CN¥587.9bCN¥92.1bCN¥17.4b68.7x33.7x6.4x
Sun, 21 Sep 2025CN¥628.7bCN¥92.1bCN¥17.4b72.8x36.1x6.8x
Tue, 19 Aug 2025CN¥600.8bCN¥91.6bCN¥17.9b64.3x33.6x6.6x
Thu, 17 Jul 2025CN¥492.7bCN¥89.8bCN¥15.4b51x32.1x5.5x
Sat, 14 Jun 2025CN¥439.9bCN¥89.8bCN¥15.4b47.3x28.6x4.9x
Mon, 12 May 2025CN¥388.3bCN¥89.3bCN¥15.1b45.2x25.6x4.3x
Wed, 09 Apr 2025CN¥358.0bCN¥88.5bCN¥14.0b36.4x25.5x4x
Fri, 07 Mar 2025CN¥440.8bCN¥89.0bCN¥11.3b45x38.9x5x
Sun, 02 Feb 2025CN¥358.6bCN¥88.1bCN¥11.2b37.6x31.9x4.1x
Tue, 31 Dec 2024CN¥371.6bCN¥87.8bCN¥11.2b37.5x33.2x4.2x
Thu, 28 Nov 2024CN¥364.4bCN¥87.8bCN¥11.2b38.8x32.6x4.1x
Sat, 26 Oct 2024CN¥388.5bCN¥88.3bCN¥12.3b37.3x31.5x4.4x
Mon, 23 Sep 2024CN¥284.4bCN¥88.2bCN¥12.4b26.8x23x3.2x
Wed, 21 Aug 2024CN¥274.8bCN¥87.5bCN¥12.5b25.3x22x3.1x
Fri, 19 Jul 2024CN¥281.6bCN¥88.3bCN¥13.4b26x21x3.2x
Sun, 16 Jun 2024CN¥308.1bCN¥88.3bCN¥13.4b27.3x23x3.5x
Tue, 14 May 2024CN¥337.4bCN¥88.3bCN¥13.3b29.5x25.3x3.8x
Thu, 11 Apr 2024CN¥335.6bCN¥90.3bCN¥15.0b33.1x22.4x3.7x
Sat, 09 Mar 2024CN¥346.8bCN¥90.5bCN¥15.5b32.4x22.4x3.8x
Mon, 05 Feb 2024CN¥325.7bCN¥91.1bCN¥16.1b29.5x20.3x3.6x
Wed, 03 Jan 2024CN¥463.2bCN¥91.1bCN¥16.1b38.7x28.8x5.1x
Fri, 01 Dec 2023CN¥531.6bCN¥91.1bCN¥16.1b38.5x33.1x5.8x
Sun, 29 Oct 2023CN¥529.7bCN¥91.7bCN¥18.3b35.8x28.9x5.8x
Tue, 26 Sep 2023CN¥498.2bCN¥92.0bCN¥18.3b33.8x27.2x5.4x
Thu, 24 Aug 2023CN¥471.4bCN¥91.6bCN¥18.6b33x25.4x5.1x
Sat, 22 Jul 2023CN¥462.1bCN¥91.3bCN¥18.5b34.9x25x5.1x
Mon, 19 Jun 2023CN¥501.6bCN¥91.3bCN¥18.5b37.7x27.2x5.5x
Price to Earnings Ratio

27.2x


Total Market Cap: CN¥501.6bTotal Earnings: CN¥18.5bTotal Revenue: CN¥91.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Chinese Clinical Research and Equipment Industry Price to Earnings3Y Average 28.7x202420252026
Current Industry PE
  • Investors are pessimistic on the Chinese Life Sciences Tools and Services industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 24.0x which is lower than its 3-year average PE of 28.7x.
  • The industry is trading close to its 3-year average PS ratio of 5.0x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have grown 5.8% per year over the last three years.
  • Revenues for these companies have grown 2.7% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Chinese Clinical Research and Equipment compare with similar industries?

CN Market-3.54%
Healthcare-2.26%
Life Sciences-1.80%
Clinical Research and Equipment-1.80%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
603259 WuXi AppTecCN¥99.713.3%
+CN¥9.4b		46.1%PE15.8x
688758 Suzhou Sepax TechnologiesCN¥19.8514.1%
+CN¥1.0b		24.1%PE59.8x
688114 MGI TechCN¥51.904.6%
+CN¥948.8m		-24.0%PS7.4x
300347 Hangzhou Tigermed ConsultingCN¥39.822.3%
+CN¥769.6m		-24.2%PE44.1x
688131 Shanghai Haoyuan ChemexpressCN¥77.052.7%
+CN¥434.8m		66.6%PE66.6x

Latest News

688621
CN¥52.26
Beijing Sun-Novo Pharmaceutical Research
7D
3.5%
1Y
3.9%
688315
CN¥12.32
Novogene
7D
-8.7%
1Y
-8.0%
300347
CN¥39.82
Hangzhou Tigermed Consulting
7D
2.3%
1Y
-24.2%
301230
CN¥34.46
PharmaResources (Shanghai)
7D
3.9%
1Y
4.5%
688758
CN¥19.85
Suzhou Sepax Technologies
7D
14.1%
1Y
24.1%
603259
CN¥99.71
WuXi AppTec
7D
3.3%
1Y
46.1%
Narrative Update • Jun 01

603259: Conviction List Inclusion And Buybacks Are Expected To Support Future Earnings

Analysts have raised their price target for WuXi AppTec from CN¥152.00 to about CN¥169.13, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E. This shift aligns with recent positive Street research attention, including the stock being added to a major APAC conviction list.
688222
CN¥26.11
HitGen
7D
-3.0%
1Y
60.4%
688114
CN¥51.90
MGI Tech
7D
4.6%
1Y
-24.0%
300759
CN¥22.38
Pharmaron Beijing
7D
-3.0%
1Y
-9.9%
301096
CN¥54.02
Hangzhou Bio-Sincerity Pharma-TechLtd
7D
-8.0%
1Y
21.6%
688046
CN¥17.82
GemPharmatech
7D
1.1%
1Y
42.7%
688710
CN¥54.26
Shanghai InnoStar Bio-tech
7D
-4.7%
1Y
61.2%
300463
CN¥8.54
Maccura BiotechnologyLtd
7D
-6.1%
1Y
-26.7%
603108
CN¥10.45
Shanghai Runda Medical Technology
7D
-10.5%
1Y
-39.4%
688238
CN¥5.35
Shanghai Obio Technology (Group)
7D
-7.8%
1Y
-11.3%
688131
CN¥77.05
Shanghai Haoyuan Chemexpress
7D
2.7%
1Y
66.6%